Literature DB >> 9626119

A defect in renal calcium conservation may contribute to the pathogenesis of postmenopausal osteoporosis.

H M Heshmati1, S Khosla, M F Burritt, W M O'Fallon, B L Riggs.   

Abstract

Although all postmenopausal women are estrogen deficient, women who have postmenopausal osteoporosis may have a defect, in addition to estrogen deficiency, that accounts for their higher rates of bone resorption and greater bone loss, relative to those who do not. To test the hypothesis that one defect is an impairment in renal calcium conservation, we measured renal calcium transport in 19 osteoporotic and 19 normal postmenopausal women, whose ages (median and 25th-75th percentile range) were 70 yr (range, 67-72) and 72 yr (range, 69-74), respectively. There was no difference between groups in values for serum ionized calcium and PTH concentrations or in renal filtered load of calcium. However, before PTH infusion, the osteoporotic women had lower (P = 0.0046) values for tubular reabsorption of calcium (TRCa) of 96.8% (range, 96.0-97.1) vs. 98.0% (range, 97.2-98.3) and higher (P = 0.0154) urinary calcium excretion of 0.194 mg/dL of glomerular filtrate (GF) (0.154-0.239) vs. 0.125 mg/dL of GF (0.103-0.173) than the normal women. After infusion of 200 U of synthetic PTH (synthetic 1-34 analog of human PTH), TRCa increased and calcium excretion decreased comparably in both groups, so that the differences between groups after intervention remained: for TRCa, 98.3% (97.7-98.6) vs. 98.9% (98.4-99.3; P = 0.0042); and for calcium excretion, 0.099 mg/dL of GF (0.080-0.138) vs. 0.066 mg/dL of GF, (0.045-0.097, P = 0.0180). In conclusion, postmenopausal women with osteoporosis have a PTH-independent defect in renal calcium conservation. This defect is of sufficient magnitude to contribute to the greater negative calcium balance in post-menopausal women with osteoporosis vs. their postmenopausal peers.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9626119     DOI: 10.1210/jcem.83.6.4854

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  10 in total

1.  Estrogen deficiency and low-calcium diet increased bone loss and urinary calcium excretion but did not alter arterial stiffness in young female rats.

Authors:  Jong-Hoon Park; Naomi Omi; Toshiya Nosaka; Ayako Kitajima; Ikuko Ezawa
Journal:  J Bone Miner Metab       Date:  2008-05-11       Impact factor: 2.626

2.  Bone disease in primary hypercalciuria.

Authors:  Stefania Sella; Catia Cattelan; Giuseppe Realdi; Sandro Giannini
Journal:  Clin Cases Miner Bone Metab       Date:  2008-05

3.  Effects of the SERM raloxifene on calcium and phosphate metabolism in healthy middle-aged men.

Authors:  Brigitte Uebelhart; François Herrmann; René Rizzoli
Journal:  Clin Cases Miner Bone Metab       Date:  2009-05

4.  Thiazide use and skeletal microstructure: Results from a multi-ethnic study.

Authors:  Hoang-Long Huynh; Lena Fan; Carmen Germosen; Mariana Bucovsky; Ivelisse Colon; Nayoung Kil; Sanchita Agarwal; Marcella Walker
Journal:  Bone Rep       Date:  2022-05-10

5.  Radiocalcium absorption is reduced in postmenopausal women with vertebral and most types of peripheral fractures.

Authors:  B E Christopher Nordin; Peter D O'Loughlin; Allan G Need; Michael Horowitz; Howard A Morris
Journal:  Osteoporos Int       Date:  2003-11-04       Impact factor: 4.507

6.  Influence of estrogen therapy on calcium, phosphorus, and other regulatory hormones in postmenopausal women: the MESA study.

Authors:  Nisha Bansal; Ronit Katz; Ian H de Boer; Bryan Kestenbaum; David S Siscovick; Andrew N Hoofnagle; Russell Tracy; Gail A Laughlin; Michael H Criqui; Mathew J Budoff; Dong Li; Joachim H Ix
Journal:  J Clin Endocrinol Metab       Date:  2013-10-03       Impact factor: 5.958

Review 7.  Epithelial Barrier Function in Gut-Bone Signaling.

Authors:  Naiomy Deliz Rios-Arce; Fraser L Collins; Jonathan D Schepper; Michael D Steury; Sandi Raehtz; Heather Mallin; Danny T Schoenherr; Narayanan Parameswaran; Laura R McCabe
Journal:  Adv Exp Med Biol       Date:  2017       Impact factor: 2.622

8.  Canagliflozin, an SGLT2 inhibitor, corrects glycemic dysregulation in TallyHO model of T2D but only partially prevents bone deficits.

Authors:  Kathryn M Thrailkill; R Clay Bunn; Sasidhar Uppuganti; Philip Ray; Iuliana Popescu; Evangelia Kalaitzoglou; John L Fowlkes; Jeffry S Nyman
Journal:  Bone       Date:  2020-09-02       Impact factor: 4.398

9.  Effectiveness of thiazides on serum and urinary calcium levels and bone mineral density in patients with osteoporosis: a systematic review and meta-analysis.

Authors:  Lei Cheng; Keyan Zhang; Zhenyong Zhang
Journal:  Drug Des Devel Ther       Date:  2018-11-14       Impact factor: 4.162

10.  In Silico Network Analysis of Ingredients of Cornus officinalis in Osteoporosis.

Authors:  Feiqi Huang; Huizhi Guo; Yuanbiao Wei; Xiao Zhao; Yangsheng Chen; Zhan Lin; Yanhui Zhou; Ping Sun
Journal:  Med Sci Monit       Date:  2021-04-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.